Engineering the future
of therapeutic medicine.
We unravel complex biology with optogenetics, chemistry, and AI for small molecule therapeutic discovery.
Agingisanintrinsicallycomplexsystemsbiologychallenge.OurIntegratedPlatformispurpose-builttounravelitsintricatenetworks.
Wecombineoptogenetics,high-throughputscreening,andcomputationalbiologytomapdiseasepathwayswithunprecedentedprecision.
OurAI-drivendiscoveryengineacceleratestheidentificationofnoveltherapeutictargetsandsmallmoleculecandidates.
Targeting Synaptic Dysfunction to restore cognitive resilience
Molsen Therapeutics is pioneering a precision approach to neurodegenerative disease that targets the synapse — the fundamental unit of neural communication — before irreversible damage occurs.
New mechanisms. Earlier intervention. Measurable outcomes.
Synaptic loss is the strongest correlate of cognitive decline in Alzheimer's and related dementias, yet current therapies focus almost exclusively on protein aggregation. By restoring synaptic maintenance pathways, we aim to preserve neural circuit integrity and slow functional decline at its source.
Molsen Therapeutics is advancing clinical programs across tauopathies, synucleinopathies, and mixed-etiology dementia — applying our integrated platform to identify compounds that protect and repair synaptic architecture in the aging brain.
Advancing two programs through the clinic
MSX-1108Tau Clearance Program
MSX-2401Synaptic Restoration Program
Our Approach
Optogenetics
01We use light-controlled genetic tools to interrogate disease-relevant pathways at millisecond resolution, pairing them with automated screening platforms that evaluate millions of compounds for on-target activity.
Medicinal Chemistry
02Our medicinal chemists design and optimize small molecules with drug-like properties from the outset — balancing potency, selectivity, and CNS penetration to advance candidates that translate from bench to clinic.
AI & Computational Biology
03Machine learning models trained on proprietary datasets accelerate every stage of our pipeline — from predicting target-compound interactions to optimizing ADMET profiles and prioritizing clinical candidates.